Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands

被引:43
作者
Hanemaaijer, Susan [1 ,2 ]
Sodihardjo, Fong [1 ]
Horikx, Annemieke [1 ]
Wensing, Michel [3 ]
De Smet, Peter A. G. M. [1 ,4 ]
Bouvy, Marcel L. [2 ]
Teichert, Martina [1 ,3 ]
机构
[1] Royal Dutch Pharmacists Assoc KNMP, NL-2514 JL The Hague, Netherlands
[2] Univ Utrecht, Fac Sci, Utrecht Inst Sci, Div Pharmacoepidemiol & Clin Pharmacol, NL-3508 TB Utrecht, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept IQ Healthcare, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands
关键词
Adherence; DOACs; Drug use patterns; Netherlands; NOACs; Non-vitamin K oral anticoagulants; ATRIAL-FIBRILLATION PATIENTS; TASK-FORCE; WARFARIN; PERSISTENCE; DABIGATRAN; MANAGEMENT; RIVAROXABAN;
D O I
10.1007/s11096-015-0174-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Non-vitamin K oral anticoagulants (NOACs) became available in the Netherlands in 2008, providing another antithrombotic treatment besides vitamin K antagonists (VKAs) and antiplatelet agents (APAs). Objective To describe the patterns of antithrombotic drug use between 2008 and 2013 by examination of dispensing data form community pharmacies in the Netherlands; to determine the concomitant use of NOACs with VKAs and APAs and switching between the drug classes; and to compare adherence to NOACs with adherence to APAs. Setting An observational retrospective study was conducted using routinely collected dispensing data from Dutch community pharmacies. Methods For each calendar year, the numbers of NOAC, VKA, and APA users were calculated. Adherence was determined for NOACs and APAs by the percentage of days covered by medication (PDC). Information on the prescribed daily dose of VKAs was unavailable. Main outcome measures Comparison of age, sex, and co-medications of users of the three drug classes; concomitant use of different antithrombotic drug classes and switching between these in each year; and mean PDC and percentages of all users with a PDC above 80 %. Results NOAC use increased during the study period to 29,687 users in 2013. In that year there were 484,024 VKA users and 1313,032 APA users. Compared with users of VKAs, NOAC users were slightly younger and more frequently used antiarrhythmic drugs and beta blockers as co-medications. Substantial numbers of patients were dispensed potentially harmful combinations in 2013: 820 subjects were dispensed NOACs together with VKAs, and 684 subjects were dispensed NOACs, VKAs, and APAs concomitantly. Mean adherence to NOACs was 84.2 % compared with 87.3 % to APA. One in four NOAC users had a PDC lower than 80 % compared with one in five APA users. Conclusion Our findings show increasing use of NOACs by outpatients. The number of patients taking potentially harmful combinations of antithrombotic drugs was substantial. Adherence to NOACs in daily practice may be suboptimal to prevent thrombotic events.
引用
收藏
页码:1128 / 1135
页数:8
相关论文
共 50 条
  • [41] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [42] Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
    Fanaroff, Alexander C.
    Vora, Amit N.
    Lopes, Renato D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A19 - A31
  • [43] Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
    Ben Zadok, O. Itzhaki
    Eisen, A.
    DIABETIC MEDICINE, 2018, 35 (05) : 548 - 556
  • [44] Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis
    Hamad, Adel Khalifa Sultan
    JOURNAL OF ACUTE DISEASE, 2022, 11 (06) : 212 - 221
  • [45] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [46] Management of venous thromboembolism with non-vitamin K oral anticoagulants: A review for nurse practitioners and pharmacists
    Schmerge, Michelle
    Earl, Sally
    Kline, Carol
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (04) : 185 - 192
  • [47] Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
    Cha, Myung-Jin
    Choi, Eue-Keun
    Han, Kyung-Do
    Lee, So-Ryoung
    Lim, Woo-Hyun
    Oh, Seil
    Lip, Gregory Y. H.
    STROKE, 2017, 48 (11) : 3040 - +
  • [48] Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years
    Tsai, Chuan-Tsai
    Liao, Jo-Nan
    Chen, Su-Jung
    Jiang, Yu-Ru
    Chen, Tzeng-Ji
    Chao, Tze-Fan
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (06)
  • [49] Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants
    Andresen, Kristoffer
    Atar, Dan
    Gjertsen, Erik
    Ghanima, Waleed
    Roseth, Svein
    Johansen, Odd Erik
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2018, 52 (03) : 156 - 162
  • [50] Management of Venous Thromboembolism in the Elderly: A Review of the Non-Vitamin K Oral Anticoagulants
    Bethishou, Laressa
    Gregorian, Tania
    Won, Kimberly
    Lopez, Kristina
    Tsu, Laura V.
    CONSULTANT PHARMACIST, 2018, 33 (05): : 248 - 261